An observational study in Acute Lymphoblastic Leukemia, Leukemia and Non-Hodgkin's Lymphoma, sponsored by Goethe University. Recruiting at 147 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Goethe University · Observational
The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial.
Acute Lymphoblastic Leukemia or seleted NHL
Inclusion Criteria:
Overall survival
Time frame: up to 10 years
Event free survival
Time frame: up to 10 years
Hematologic remission rate
Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Molecular remission rate
Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Positron Emission Tomography (PET) based remission evaluation
Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Remission duration
Time frame: up to 10 years
Relapse rate
Time frame: up to 10 years
Disease free survival
Time frame: up to 10 years
Early mortality
Time frame: during induction therapy with a duration of approximately 6 - 8 weeks
Mortality in Clinical Remission (CR)
Time frame: up to 10 years
Comorbidities
Time frame: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified
Quality of life assessed by Quality of Life Questionnaire (QLQ-C30)
Time frame: after treatment which is approximately 2.5 years from diagnosis
Eastern Cooperative Oncology Group (ECOG) status
Time frame: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified
Toxicities assessed by CTCAE v4.03
Time frame: during treatment with an approximate duration of 2.5 years from diagnosis
Showing the first 100 of 147 sites across 2 countries.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma→
Goethe University